BioGaia AB establishes direct sales in the Netherlands

BioGaia AB (NASDAQ: BIOG) is expanding its global footprint by establishing direct sales in the Netherlands initially through an online approach. BioGaia will launch sales of its products on the major local marketplaces, Bol.com and Amazon.nl. This initiative supports BioGaia’s long-term strategy to expand through direct sales and bring its clinically proven probiotics closer to consumers.

The Netherlands is one of the last countries in Europe where our products are not yet available through our own direct sales or a distributor. Given the strong potential and increasing interest in probiotics in the Netherlands, it is a natural step for us to explore this opportunity, gain insights, and work to meet the growing local demand.

Theresa Agnew, President and CEO of BioGaia, stated: “The Netherlands represents an exciting opportunity for BioGaia. By employing a cost-efficient and streamlined go-to-market approach, we can effectively explore the potential of this market before deciding whether to establish local operations. This strategy enables us to leverage our global expertise to provide enhanced support to retailers and consumers. It also aligns with our business-to-consumer strategy, building on the success we’ve achieved in other direct markets.”
 

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Sebastian Heimfors, Chief Commercial Officer, BioGaia AB
Email: [email protected]
Phone: +46(0)8 555 293 00

About BioGaia
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com